Loading…
Jamol Laboratories, Inc. was cited for manufacturing adulterated over-the-counter Ponaris Nasal Emollient drug products under insanitary conditions and in violation of Current Good Manufacturing Practice (CGMP) regulations. During a December 2022 to January 2023 inspection of their Emerson, New Jersey facility, FDA investigators found the multipurpose manufacturing space in a state of disrepair with poor cleaning and maintenance, including a dead insect, exposed ceiling, inadequate ventilation, and debris-covered equipment positioned in a corridor. The firm lacked adequate controls to maintain a clean production environment and prevent product contamination, resulting in violations of 21 CFR parts 210 and 211 governing finished pharmaceutical manufacturing.